Oncolys BioPharma (TSE:4588) Stock Based Compensation: 円0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4588 Oncolys BioPharma Inc TSE:4588
37 GF Score
Price 円2,665.00
GF Value 円359.32
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Oncolys BioPharma Stock Based Compensation?

Oncolys BioPharma TSE:4588 +8.20% 37 Stock Based Compensation is 円0.00 Mil as of Dec. 2025. GuruFocus rates TSE:4588 with a GF Score™ of 37/100 and a GF Value™ of 円359.32 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Oncolys BioPharma's Stock Based Compensation for the three months ended in Dec. 2025 was 円0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was 円0.00 Mil.

Oncolys BioPharma Stock Based Compensation Related Terms

Oncolys BioPharma Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Oncolys BioPharma's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncolys BioPharma Stock Based Compensation Chart

Oncolys BioPharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 208.95 58.13 9.43 19.43 41.73

Oncolys BioPharma Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4588
37GF Score
Oncolys BioPharma Inc TSE:4588
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncolys BioPharma Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.

What does a Stock Based Compensation of 円0.00 Mil mean?
Oncolys BioPharma (TSE:4588) has a Stock Based Compensation of 円0.00 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Oncolys BioPharma and its competitors.
Is Oncolys BioPharma's Stock Based Compensation too high?
Oncolys BioPharma's current Stock Based Compensation is 円0.00 Mil. Overall, Oncolys BioPharma has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncolys BioPharma's Stock Based Compensation compare to VRTX and REGN?
Oncolys BioPharma's Stock Based Compensation of 円0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Oncolys BioPharma and its competitors. Oncolys BioPharma's current Stock Based Compensation is 円0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolys BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Oncolys BioPharma (TSE:4588) is currently considered Significantly Overvalued. The stock's GF Value™ is 円359.32, compared to a current price of 円2,665.00 — trading 641.7% above its estimated fair value. The current Stock Based Compensation is 円0.00 Mil. Oncolys BioPharma's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Oncolys BioPharma (TSE:4588), the current Stock Based Compensation is 円0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncolys BioPharma (TSE:4588) Overvalued in 2026?

Based on GuruFocus' analysis, Oncolys BioPharma stock appears to be overvalued. The current stock price of 円2,665.00 is trading 641.7% above its estimated GF Value™ of 円359.32. GuruFocus considers Oncolys BioPharma to be Significantly Overvalued.

Key valuation signals for TSE:4588:

  • Stock Based Compensation: 円0.00 Mil
  • GF Value™: 円359.32 vs. price of 円2,665.00 (641.7% above fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the TSE:4588 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncolys BioPharma Business Description

Address 4-1-28 Toranomon, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
37GF Score

Get the complete analysis for TSE:4588

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,665.00
Price
円359.32
GF Value